As Novo Nordisk continues its epic battle with Eli Lilly for market share in the increasingly competitive obesity and diabetes space, Novo is launching a major rebranding of its business, its logo and its name.
WuXi AppTec’s Ke Chen discusses trends reshaping API manufacturing – while diligence, understanding and controlling the process remains the cornerstone
Why are so many eligible patients still missing the therapies designed for them?
Why aren’t diagnostic-driven therapies reaching enough patients?
Real-world data has become table stakes. The next challenge is connecting it to genetic insight that can sharpen R&D decisions.
Dr. Rana McKay speaks to the ARANOTE trial of NUBEQA® (darolutamide) and what the data mean for patients, doctors, and care providers.
GSK is advancing its inaugural lung cancer asset, Jideytro, toward a landmark first-line FDA approval, aided by an unprecedented complete response rate.
A preliminary 15% higher death risk in a phase 3 trial threatens to thwart AstraZeneca and Daiichi Sankyo’s bid to establish their star ADC Enhertu as a first-line treatment for patients with HER2-mutant non-small cell lung cancer.